← Back to front page
United States · Platforms & data · MarketWatch

The FDA declined to approve one of biotech’s most closely watched cancer drugs

Published by MarketWatch · United States 30 min ago
The FDA declined to approve one of biotech’s most closely watched cancer drugs
MarketWatch

Detailed summary

The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.

Read the full article on MarketWatch Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketwatch.com)

Also worth reading